|
JP5824040B2
(ja)
*
|
2010-06-01 |
2015-11-25 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ |
置換イミダゾピラジン
|
|
CA3007787C
(en)
|
2010-06-03 |
2020-03-10 |
Pharmacyclics Llc |
The use of inhibitors of bruton's tyrosine kinase (btk)
|
|
WO2012170827A2
(en)
*
|
2011-06-08 |
2012-12-13 |
Cylene Pharmaceuticals, Inc. |
Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
|
|
US9309250B2
(en)
|
2011-06-22 |
2016-04-12 |
Vertex Pharmaceuticals Incorporated |
Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
|
|
MX355667B
(es)
*
|
2012-04-27 |
2018-04-25 |
Nippon Steel & Sumitomo Metal Corp |
Tuberia de acero sin soldadura y metodo para producir la misma.
|
|
JP6280546B2
(ja)
|
2012-06-26 |
2018-02-14 |
デル マー ファーマシューティカルズ |
ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
|
|
TW201414737A
(zh)
*
|
2012-07-13 |
2014-04-16 |
必治妥美雅史谷比公司 |
作爲激酶抑制劑之咪唑并三□甲腈
|
|
CN104704129A
(zh)
|
2012-07-24 |
2015-06-10 |
药品循环公司 |
与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
|
|
SI2941432T1
(en)
|
2012-12-07 |
2018-07-31 |
Vertex Pharmaceuticals Incorporated |
2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
|
|
ES2649156T3
(es)
|
2013-01-14 |
2018-01-10 |
Incyte Holdings Corporation |
Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
|
|
PE20191245A1
(es)
|
2013-01-15 |
2019-09-18 |
Incyte Holdings Corp |
Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
|
|
WO2014143240A1
(en)
|
2013-03-15 |
2014-09-18 |
Vertex Pharmaceuticals Incorporated |
Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
|
|
US8957078B2
(en)
|
2013-03-15 |
2015-02-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
EP2970288A1
(en)
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
KR20160061911A
(ko)
|
2013-04-08 |
2016-06-01 |
데니스 엠. 브라운 |
최적하 투여된 화학 화합물의 치료 효과
|
|
CN103360399B
(zh)
*
|
2013-08-02 |
2016-03-02 |
北京大学 |
6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物，其制备方法及用途
|
|
EA201690458A1
(ru)
|
2013-08-23 |
2016-07-29 |
Инсайт Корпорейшн |
Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
|
|
CN103570728B
(zh)
*
|
2013-11-12 |
2015-12-30 |
山东大学 |
一种取代吡唑并[1,5-a]嘧啶类衍生物及其制备方法与应用
|
|
PT3077397T
(pt)
|
2013-12-06 |
2020-01-22 |
Vertex Pharma |
Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
|
|
ES2702126T3
(es)
*
|
2013-12-10 |
2019-02-27 |
Bristol Myers Squibb Co |
Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
|
|
TWI534148B
(zh)
*
|
2014-02-13 |
2016-05-21 |
生華生物科技股份有限公司 |
吡唑並嘧啶前藥及其使用方法
|
|
GB201403093D0
(en)
*
|
2014-02-21 |
2014-04-09 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
SG11201607895PA
(en)
*
|
2014-05-28 |
2016-12-29 |
Novartis Ag |
Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
|
|
MX373102B
(es)
|
2014-06-05 |
2020-04-17 |
Vertex Pharma |
Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo.
|
|
SG11201610500WA
(en)
|
2014-06-17 |
2017-01-27 |
Vertex Pharma |
Method for treating cancer using a combination of chk1 and atr inhibitors
|
|
US9822124B2
(en)
|
2014-07-14 |
2017-11-21 |
Incyte Corporation |
Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
|
|
US9580418B2
(en)
|
2014-07-14 |
2017-02-28 |
Incyte Corporation |
Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
|
|
CN105457029A
(zh)
*
|
2014-09-29 |
2016-04-06 |
中国科学院上海巴斯德研究所 |
抑制酪蛋白激酶2活性在促进i型干扰素表达的应用
|
|
EP3230279A1
(en)
*
|
2014-12-10 |
2017-10-18 |
Massachusetts Institute of Technology |
Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
|
|
TWI726861B
(zh)
*
|
2015-01-23 |
2021-05-11 |
英商葛蘭素史克智慧財產發展有限公司 |
吡唑并-嘧啶化合物、其鹽及其用途
|
|
WO2016196244A1
(en)
|
2015-05-29 |
2016-12-08 |
Incyte Corporation |
Pyridineamine compounds useful as pim kinase inhibitors
|
|
TWI734699B
(zh)
|
2015-09-09 |
2021-08-01 |
美商英塞特公司 |
Ｐｉｍ激酶抑制劑之鹽
|
|
AU2016331955B2
(en)
|
2015-09-30 |
2022-07-21 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
|
|
US9920032B2
(en)
|
2015-10-02 |
2018-03-20 |
Incyte Corporation |
Heterocyclic compounds useful as pim kinase inhibitors
|
|
KR20180107261A
(ko)
|
2016-02-16 |
2018-10-01 |
메사추세츠 인스티튜트 오브 테크놀로지 |
Myc 조정제로서의 MAX 결합제 및 그의 용도
|
|
CN109562111B
(zh)
*
|
2016-06-24 |
2023-04-04 |
北极星药业股份有限公司 |
Ck2抑制剂，其组合物及方法
|
|
MX2019012431A
(es)
|
2017-04-21 |
2020-08-03 |
Ikena Oncology Inc |
Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
|
|
CN107188901A
(zh)
*
|
2017-05-27 |
2017-09-22 |
无锡捷化医药科技有限公司 |
一种(3‑(3‑(二甲氨基)丙氧基)苯基)硼酸的制备方法
|
|
SI3658557T1
(sl)
|
2017-07-28 |
2024-10-30 |
Takeda Pharmaceutical Company Limited |
Zaviralci TYK2 in njihova uporaba
|
|
SG11201913517UA
(en)
|
2017-07-28 |
2020-02-27 |
Yuhan Corp |
Improved process for preparing aminopyrimidine derivatives
|
|
GB201715194D0
(en)
|
2017-09-20 |
2017-11-01 |
Carrick Therapeutics Ltd |
Compounds and their therapeutic use
|
|
WO2019113487A1
(en)
|
2017-12-08 |
2019-06-13 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
|
US11071727B2
(en)
|
2018-01-26 |
2021-07-27 |
Northwestern University |
Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
|
|
US11155560B2
(en)
|
2018-10-30 |
2021-10-26 |
Kronos Bio, Inc. |
Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity
|
|
CN112028891B
(zh)
*
|
2019-07-30 |
2022-07-05 |
厦门宝太生物科技股份有限公司 |
腺苷受体拮抗剂
|
|
AU2020394424A1
(en)
|
2019-11-26 |
2022-06-16 |
Ikena Oncology, Inc. |
Polymorphic carbazole derivatives and uses thereof
|
|
GB201918541D0
(en)
|
2019-12-16 |
2020-01-29 |
Carrick Therapeutics Ltd |
Therapeutic compounds and their use
|
|
KR102337404B1
(ko)
*
|
2020-01-03 |
2021-12-10 |
연세대학교 산학협력단 |
조직 재생용 조성물
|
|
AU2021249224A1
(en)
*
|
2020-03-30 |
2022-12-01 |
Senhwa Biosciences, Inc. |
Antiviral compounds and method for treating hepatotropic viral infection, particularly hepatitis B and hepatitis D
|
|
KR20230069126A
(ko)
*
|
2020-09-15 |
2023-05-18 |
미쓰비시 타나베 파마 코퍼레이션 |
트리아진 화합물의 염, 그 결정형 및 제조 방법
|
|
CN115867553B
(zh)
*
|
2021-01-09 |
2026-03-06 |
巴格沃克斯研究有限公司 |
作为腺苷2A受体和腺苷2B受体拮抗剂的二氨基吡唑[1, 5-a]并嘧啶-6-腈化合物
|
|
US12343421B2
(en)
*
|
2021-11-01 |
2025-07-01 |
Solaana MD LLC |
Vitamin D base layer
|
|
EP4676476A1
(en)
*
|
2023-03-09 |
2026-01-14 |
Aquinnah Pharmaceuticals, Inc. |
Inhibitors of tdp-43 and tau aggregation
|
|
US12269826B1
(en)
*
|
2023-11-16 |
2025-04-08 |
King Faisal University |
7H-pyrido[4′,3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds as CK2 inhibitors
|